Overview

ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This is a pilot study investigating the efficacy of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in adults living with HIV-1 experiencing virological failure on first-line Efavirenz-based antiretroviral therapy with non-nucleoside reverse transcriptase inhibitor resistance

Phase:

Phase 3

Details

Lead Sponsor:

Professor Francois Venter
Willem Daniel Francois Venter

Treatments:

Lamivudine
Tenofovir